

Vaxcyte announced positive Phase 3 OPUS-1 trial results for its VAX-31 vaccine candidate, setting the stage for an FDA BLA filing.
You can purchase shares of Vaxcyte (NASDAQ:PCVX) through any online brokerage.
Other companies in Vaxcyte’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Moderna Inc (NASDAQ:MRNA).
Vaxcyte has a consensus price target of $122.18.
The stock price for Vaxcyte (NASDAQ: PCVX) is $64.05 last updated November 6, 2026 at 6:38 PM EST.
There are no upcoming dividends for Vaxcyte.
Vaxcyte does not have any upcoming earnings scheduled.
There is no upcoming split for Vaxcyte.
Vaxcyte is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel...